Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > Articles online first > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2021 Dec 09

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2021 Dec 09

DOI: 10.23736/S1824-4785.21.03411-7

Copyright © 2021 EDIZIONI MINERVA MEDICA

language: English

Side effects of theragnostic agents currently employed in clinical practice

Alessio RIZZO 1 , Salvatore ANNUNZIATA 2, Massimo SALVATORI 3

1 Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy; 2 Unità di Medicina Nucleare, TracerGLab, Dipartimento Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy; 3 Istituto di Medicina Nucleare, Università Cattolica del Sacro Cuore, Rome, Italy


PDF


Nuclear medicine plays an increasingly important role in several neoplasms management through a theragnostic approach by which targeted molecular imaging and radiotherapy are obtained with the use of radionuclide pairs with similar characteristics. In some cases, nuclear theragnostic use a pair of agents with identical chemical and biological characteristics while in others are employed theragnostic molecules which are not chemically or biologically identical but show similar biodistribution (so-called “twins in spirit” radiopharmaceuticals). This strategy was developed for the first time over 75 years ago, when Iodine-131 was used for diagnostic imaging, confirmation of target expression and radionuclide therapy of thyroid cancer. Other theragnostic approaches were subsequently introduced with significant clinical results and some of them are currently considered standard treatment for different cancers. However, as any other therapy, also nuclear theragnostic treatment carries the potential risk of early deterministic and late stochastic off-target adverse effects, generally minimal and easily managed. This article reviews the reported side effects and risks of the main radiopharmaceuticals used for nuclear theragnostic in oncology for the treatment of thyroid cancer, neuroendocrine neoplasms, adrenergic tumours, metastatic prostate cancer, and liver tumours. Selecting appropriate patients using a multidisciplinary approach, meticulous pre-treatment planning and knowledge of methods permit to decrease the incidence of these potential side effects.


KEY WORDS: Radiopharmaceuticals; Side Effects; Theragnostic; Review

top of page